(Bloomberg) -- Vertex Pharmaceuticals ... sickle cell disease and beta thalassemia that was developed in collaboration with Crispr Therapeutics AG. Vertex is also studying a kidney drug, called ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...